Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL?

Imagem de Miniatura
Arquivos
art_COUTO_Autologous_allogeneic_hematopoietic_cell_transplantation_and_CARTNK_therapy_2023.PDF (956.32 KB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
Citação
FRONTIERS IN ONCOLOGY, v.13, article ID 1195759, 19p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Peripheral T cell lymphoma (PTCL) is a rare and aggressive type of non-Hodgkin's lymphoma that affects mature T cells. This type of cancer is characterized by the abnormal growth of T cells, which can accumulate in the lymph nodes, spleen, bone marrow, and other organs, leading to a variety of symptoms. PTCLs are often difficult to diagnose and treat, and they have a poorer prognosis than other types of lymphoma. However, recent advancements in treatment options, such as targeted therapies have shown promise in improving outcomes for patients with PTCL. Here, we discuss the use of autologous and allogeneic hematopoietic cell transplantation (HCT) as a treatment strategy for patients with PTCL, as well as the recent treatment approaches based on advanced cellular therapy. The current evidence for the use of HCT in PTCL is mainly derived from registry data, retrospective studies, and expert opinion, as randomized trials are limited due to the low incidence and histological heterogeneity of PTCL subtypes.
Palavras-chave
hematopoietic cell transplantation, peripheral T-cell lymphoma, CAR-T cell, CAR-NK cell, immunotherapy
URI
https://observatorio.fm.usp.br/handle/OPI/56001
Referências
  1. Abeyakoon C, 2020, CANCERS, V12, DOI 10.3390/cancers12113125
  2. Al-Mansour Z, 2019, LEUKEMIA LYMPHOMA, V60, P1934, DOI 10.1080/10428194.2018.1563691
  3. Alaggio R, 2022, LEUKEMIA, V36, P1720, DOI 10.1038/s41375-022-01620-2
  4. Altvater B, 2009, CLIN CANCER RES, V15, P4857, DOI 10.1158/1078-0432.CCR-08-2810
  5. Barrett DM, 2011, HUM GENE THER, V22, P1575, DOI 10.1089/hum.2011.070
  6. Beatty GL, 2014, CANCER IMMUNOL RES, V2, P112, DOI 10.1158/2326-6066.CIR-13-0170
  7. Bednarski JJ, 2022, BLOOD, V139, P1670, DOI 10.1182/blood.2021013972
  8. Bellei M, 2018, HAEMATOLOGICA, V103, P1191, DOI 10.3324/haematol.2017.186577
  9. Birkholz K, 2009, GENE THER, V16, P596, DOI 10.1038/gt.2008.189
  10. Birnbaum ME, 2014, P NATL ACAD SCI USA, V111, P17576, DOI 10.1073/pnas.1420936111
  11. Capsomidis A, 2018, MOL THER, V26, P354, DOI 10.1016/j.ymthe.2017.12.001
  12. Picanço-Castro V, 2020, HEMATOL TRANSF CELL, V42, P150, DOI 10.1016/j.htct.2019.06.007
  13. Pinz KG., 2017, TARGETING T CELL MAL
  14. Prager I, 2019, J LEUKOCYTE BIOL, V105, P1319, DOI 10.1002/JLB.MR0718-269R
  15. Querfeld C, 2018, CANCER IMMUNOL RES, V6, P900, DOI 10.1158/2326-6066.CIR-17-0270
  16. Raikar SS, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1407898
  17. Ramos RN, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.784421
  18. Rasaiyaah J, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99442
  19. Rashidi A, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.43
  20. Reimer P, 2009, J CLIN ONCOL, V27, P106, DOI 10.1200/JCO.2008.17.4870
  21. Rodríguez J, 2003, ANN ONCOL, V14, P1768, DOI 10.1093/annonc/mdg459
  22. Rodríguez J, 2007, EUR J HAEMATOL, V79, P32, DOI 10.1111/j.1600-0609.2007.00856.x
  23. Rogers AM, 2020, CURR HEMATOL MALIG R, V15, P316, DOI 10.1007/s11899-020-00590-5
  24. Rohlfing S, 2018, ANN HEMATOL, V97, P1241, DOI 10.1007/s00277-018-3288-7
  25. Rowan AG, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1118681
  26. Savage KJ, 2022, BLOOD ADV, V6, P5550, DOI 10.1182/bloodadvances.2020003971
  27. Schmitz N, 2021, BLOOD, V137, P2646, DOI 10.1182/blood.2020008825
  28. Schönfeld K, 2015, MOL THER, V23, P330, DOI [10.1038/mt.2014.21, 10.1038/mt.2014.219]
  29. Shen KN, 2017, ANN HEMATOL, V96, P687, DOI 10.1007/s00277-017-2929-6
  30. Shimasaki N, 2012, CYTOTHERAPY, V14, P830, DOI 10.3109/14653249.2012.671519
  31. Shustov AR, 2010, BRIT J HAEMATOL, V150, P170, DOI 10.1111/j.1365-2141.2010.08210.x
  32. Sieniawski M, 2010, BLOOD, V115, P3664, DOI 10.1182/blood-2009-07-231324
  33. Simonetta F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00465
  34. Smith SM, 2013, J CLIN ONCOL, V31, P3100, DOI 10.1200/JCO.2012.46.0188
  35. Svoboda J., 2018, BRIEF REPORT CLIN TR
  36. Tan Y, 2023, J HEMATOL ONCOL, V16, DOI 10.1186/s13045-023-01427-3
  37. Tonn T, 2013, CYTOTHERAPY, V15, P1563, DOI 10.1016/j.jcyt.2013.06.017
  38. Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200/JCO.2008.16.4558
  39. Weiner DM, 2021, J AM ACAD DERMATOL, V84, P597, DOI 10.1016/j.jaad.2020.12.026
  40. Weisenburger DD, 2011, BLOOD, V117, P3402, DOI 10.1182/blood-2010-09-310342
  41. Wilhelm M, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.63
  42. Wulf G, 2019, BONE MARROW TRANSPL, V54, P877, DOI 10.1038/s41409-018-0360-9
  43. Xu YX, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0732-7
  44. Yam C, 2016, AM J HEMATOL, V91, P672, DOI 10.1002/ajh.24372
  45. Zhang JY, 2018, AM J HEMATOL, V93, P394, DOI 10.1002/ajh.24992
  46. Zhang YQ, 2023, BLOOD CANCER J, V13, DOI 10.1038/s41408-023-00822-w
  47. Chen AI, 2008, BIOL BLOOD MARROW TR, V14, P741, DOI 10.1016/j.bbmt.2008.04.004
  48. Chen KH, 2017, LEUKEMIA, V31, P2151, DOI 10.1038/leu.2017.8
  49. Chen KH., 2016, NOVEL ANTI CD3 CHIME
  50. Chen Y, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.944511
  51. Chiesa R, 2023, NEW ENGL J MED, DOI 10.1056/NEJMoa2300709
  52. Chu J, 2014, LEUKEMIA, V28, P917, DOI 10.1038/leu.2013.279
  53. Cooper ML, 2018, LEUKEMIA, V32, P1970, DOI 10.1038/s41375-018-0065-5
  54. Corradini P, 2006, LEUKEMIA, V20, P1533, DOI 10.1038/sj.leu.2404306
  55. Corradini P, 2004, J CLIN ONCOL, V22, P2172, DOI 10.1200/JCO.2004.12.050
  56. Czajczynska A, 2013, BIOL BLOOD MARROW TR, V19, P1632, DOI 10.1016/j.bbmt.2013.07.003
  57. d'Amore F, 2012, J CLIN ONCOL, V30, P3093, DOI 10.1200/JCO.2011.40.2719
  58. Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166
  59. Daher M, 2021, CANCER DISCOV, V11, P45, DOI 10.1158/2159-8290.CD-20-0556
  60. Delioukina M, 2012, BONE MARROW TRANSPL, V47, P65, DOI 10.1038/bmt.2011.16
  61. DELLABONA P, 1994, J EXP MED, V180, P1171, DOI 10.1084/jem.180.3.1171
  62. Di Stasi A, 2011, NEW ENGL J MED, V365, P1673, DOI 10.1056/NEJMoa1106152
  63. Dodero A, 2012, LEUKEMIA, V26, P520, DOI 10.1038/leu.2011.240
  64. Du J, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.9807
  65. El-Asmar J, 2016, BIOL BLOOD MARROW TR, V22, P802, DOI 10.1016/j.bbmt.2015.12.004
  66. Epperla N, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-018-0696-z
  67. Fathi E, 2020, BLOOD RES, V55, P10, DOI 10.5045/br.2020.55.1.10
  68. Firor AE, 2015, EXP BIOL MED, V240, P1087, DOI 10.1177/1535370215584936
  69. Foss FM, 2020, AM J HEMATOL, V95, P151, DOI 10.1002/ajh.25674
  70. Glienke W, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00021
  71. Godfrey DI, 2004, J CLIN INVEST, V114, P1379, DOI 10.1172/JCI200423594
  72. Gomes-Silva D, 2017, BLOOD, V130, P285, DOI 10.1182/blood-2017-01-761320
  73. Gonzalez BR, 2016, CURR OPIN ONCOL, V28, P88, DOI 10.1097/CCO.0000000000000243
  74. Harrer DC, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3539-3
  75. Heczey A, 2020, NAT MED, V26, P1686, DOI 10.1038/s41591-020-1074-2
  76. Horwitz S, 2022, ANN ONCOL, V33, P288, DOI 10.1016/j.annonc.2021.12.002
  77. Horwitz SM, 2022, J NATL COMPR CANC NE, V20, P285, DOI 10.6004/jnccn.2022.0015
  78. Houghtelin A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01272
  79. Hu YX, 2022, CELL RES, V32, P995, DOI 10.1038/s41422-022-00721-y
  80. Huang HW, 2017, BIOL BLOOD MARROW TR, V23, P1393, DOI 10.1016/j.bbmt.2017.04.021
  81. Jacobsen ED, 2011, ANN ONCOL, V22, P1608, DOI 10.1093/annonc/mdq698
  82. Jamal S., 2001, IMMUNOPHENOTYPIC ANA
  83. Jantunen E, 2004, BONE MARROW TRANSPL, V33, P405, DOI 10.1038/sj.bmt.1704367
  84. Jantunen E, 2013, BLOOD, V121, P2529, DOI 10.1182/blood-2012-11-466839
  85. Kharfan-Dabaja MA, 2017, BIOL BLOOD MARROW TR, V23, P1826, DOI 10.1016/j.bbmt.2017.07.027
  86. Kruschinski A., 2008, ENG ANTIGEN SPECIFIC
  87. Lansigan F, 2020, ACTA HAEMATOL-BASEL, V143, P40, DOI 10.1159/000500666
  88. Le Gouill S, 2008, J CLIN ONCOL, V26, P2264, DOI 10.1200/JCO.2007.14.1366
  89. Liu E, 2018, LEUKEMIA, V32, P520, DOI 10.1038/leu.2017.226
  90. Liu EL, 2020, NEW ENGL J MED, V382, P545, DOI 10.1056/NEJMoa1910607
  91. Lu PH, 2022, BLOOD, V140, P321, DOI 10.1182/blood.2021014498
  92. Maciocia PM, 2017, NAT MED, V23, P1416, DOI 10.1038/nm.4444
  93. Mamonkin M, 2015, BLOOD, V126, P983, DOI 10.1182/blood-2015-02-629527
  94. Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755
  95. McCarthy NE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00985
  96. Melenhorst JJ, 2010, BLOOD, V116, P4700, DOI 10.1182/blood-2010-06-289991
  97. Mercadal S, 2008, ANN ONCOL, V19, P958, DOI 10.1093/annonc/mdn022
  98. Morton LT, 2020, MOL THER, V28, P64, DOI 10.1016/j.ymthe.2019.10.001
  99. Nielsen MM, 2017, NAT REV IMMUNOL, V17, P733, DOI 10.1038/nri.2017.101
  100. Nijeboer P, 2015, AM J HEMATOL, V90, P493, DOI 10.1002/ajh.23992
  101. O'Connor OA, 2015, J CLIN ONCOL, V33, P2492, DOI 10.1200/JCO.2014.59.2782
  102. O'Connor OA, 2011, J CLIN ONCOL, V29, P1182, DOI 10.1200/JCO.2010.29.9024
  103. Pan J, 2021, J CLIN ONCOL, V39, P3340, DOI 10.1200/JCO.21.00389
  104. Papadopoulou A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008825
  105. Park SI, 2019, CANCER-AM CANCER SOC, V125, P1507, DOI 10.1002/cncr.31861
  106. Perera LP, 2017, AM J HEMATOL, V92, P892, DOI 10.1002/ajh.24794
  107. Phillips EH, 2019, BONE MARROW TRANSPL, V54, P465, DOI 10.1038/s41409-018-0294-2

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/13
Artigos e Materiais de Revistas Científicas - LIM/31
Carregar mais